<DOC>
	<DOCNO>NCT00118235</DOCNO>
	<brief_summary>This phase II trial study well give cisplatin irinotecan together bevacizumab work treat patient extensive-stage small cell lung cancer . Drugs use chemotherapy , cisplatin irinotecan , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth small cell lung cancer block blood flow tumor . Giving cisplatin irinotecan together bevacizumab may kill tumor cell .</brief_summary>
	<brief_title>Cisplatin , Irinotecan , Bevacizumab , Treating Patients With Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine percentage patient extensive stage small cell lung cancer treat cisplatin , irinotecan bevacizumab live longer 12 month . SECONDARY OBJECTIVES : I . To assess response rate patient treat cisplatin , irinotecan bevacizumab . II . To evaluate toxicity tolerability combination cisplatin , irinotecan bevacizumab . III . To determine association VEGF/KDR complex expression VEGF plasma level tumor response . OUTLINE : Patients receive cisplatin IV 60 minute irinotecan IV 90 minute day 1 8 . Patients also receive bevacizumab IV 30-90 minute day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year every 6 month 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>All patient must histologically cytologically document small cell carcinoma bronchus The extensive disease classification protocol include patient disease site define limited stage ; limited stage disease category include patient disease restrict one hemithorax regional lymph node metastasis , include hilar , ipsilateral contralateral mediastinal , and/or ipsilateral supraclavicular node ; extensive stage patient define patient extrathoracic metastasis , malignant pleural effusion , bilateral contralateral supraclavicular adenopathy contralateral hilar adenopathy Measurable Nonmeasurable Disease No prior chemotherapy investigational therapy SCLC Radiation therapy must complete least three week initiation protocol therapy No major surgical procedure within 28 day prior start treatment fully recover No minor surgical procedure ( mediastinoscopy core biopsy ) within 7 day prior start treatment ECOG performance status : 02 No `` currently active '' second malignancy nonmelanoma skin cancers No CNS metastasis ; patient history CNS metastases NOT eligible even complete course CNS radiotherapy ; patient screen brain CT MRI rule occult CNS metastases No recent history CVA ( within 6 month ) No serious nonhealing wound ulcer bone fracture Patients history significant bleeding episode ( e.g. , hemoptysis , bleed diathesis , upper low GI bleed ) eligible ; patient trace blood sputum ( `` blood ting sputum '' ) eligible No myocardial infarction significant change anginal pattern within one year current congestive heart failure ( NYHA Class 2 high ) Patients history hypertension must well control ( &lt; 150/90 ) stable regimen antihypertensive therapy No HIVpositive patient receive combination antiretroviral therapy possible pharmacokinetic interaction protocol treatment ; ( patient immune deficiency increase risk lethal infection treat marrowsuppressive therapy ) No chronic daily treatment aspirin ( &gt; 325 mg/day ) nonsteroidal antiinflammatory agent know inhibit platelet function ; treatment dipyridamole ( Persantine ) , ticlopidine ( Ticlid ) , clopidogrel ( Plavix ) , cilostazol ( Pletal ) , antiplatelet agent No clinically significant peripheral neuropathy ( grade &gt; = 2 ) No know hypersensitivity Chinese hamster ovary cell product recombinant human antibodies No treatment therapeutic anticoagulation ; prophylactic anticoagulation central venous access device allow provided requirement INR &lt; 1.5 PTT &lt; 1.2 x ULN meet ; caution take treat patient low dose heparin low molecular weight heparin DVT prophylaxis may increase bleed risk bevacizumab No current and/or recent ( within 1 month ) use thrombolytic agent ; low dose thrombolytic therapy maintenance central venous catheter allow No clinically significant peripheral arterial disease Nonpregnant nonnursing ; effect combination bevacizumab , cisplatin , irinotecan fetus infant unknown Granulocytes &gt; = 1,500/μl Platelets &gt; = 100,000/μl Serum Creatinine = &lt; ULN Total Bilirubin &lt; 2.0 mg/dl SGOT &lt; 2 x ULN INR &lt; 1.5 PTT &lt; 1.2 x ULN Urine protein ( dipstick ) &lt; 1+</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>